Ubrogepant best treatment option for relieving mild migraine pain: Study

The key highlights of this study were:

1. There are details on 19,291 hits from 808 participants.

2. For attacks treated with ubrogepant-50mg when the pain was modest as opposed to moderate or severe, 2hPF rates were greater.

3. Following therapy for mild pain as opposed to moderate or severe pain, rates of relief from photophobia, phonophobia, and nausea 2 hours after treatment were similarly considerably greater.

4. For both ubrogepant dosages, the proportion of attacks with the normal function was more than twice as high at two hours. 

5. Upper respiratory tract infection was the most frequent adverse event (11% of both dosages).

6. For ubrogepant-50mg and ubrogepant-100mg, respectively, 2% and 3% of patients experienced serious adverse effects.

"Treatment with ubrogepant during mild pain resulted in significantly higher rates of freedom from pain, freedom from associated symptoms, and achieving normal function two hours after administration relative to attacks treated with moderate or severe pain," the researchers conclude. 

Reference: 

Lipton, R. B., Dodick, D., Goadsby, P. J., Burstein, R., Adams, A. M., Lai, J., Yu, S. Y., Finnegan, M., Kuang, A. W., & Trugman, J. M. (2022). Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain Versus Moderate or Severe Pain. In Neurology (p. 10.1212/WNL.0000000000201031). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1212/wnl.0000000000201031